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 Summary 
Aim 
Performance Measures (PMs) for Australian laboratories reporting cervical cytology 
are a set of quantifiable measures relating to the profile and accuracy of reporting. 
This study reviews aggregate data collected over the ten years in which participation 
in the PMs has been mandatory. 
 
Method 
Laboratories submit annual data on PMs relating to the profile of reporting, including 
reporting rates for technically unsatisfactory specimens, high grade (HG) or possible 
HG abnormalities and abnormal reports. Cytology-histology correlation data and 
review findings of negative smears reported from women with histological HG 
disease are also collected. Suggested acceptable standards are set for each 
measure. 
 
This study reviews the aggregate data submitted by all laboratories for the years 
1998-2008 and examines trends in reporting and the performance of laboratories 
against the suggested standards. 
 
Results 
The performance of Australian laboratories has shown continued improvement over 
the study period. There has been a fall in the proportion of laboratories with data 
outside the acceptable standard range in all PMs.  
 
Laboratories are reporting a greater proportion of specimens as definite or possible 
HG abnormality. This is partly attributable to an increase in the proportion of 
abnormal results classified as HG or possible HG abnormality. Despite this, the 
positive predictive value for HG and possible HG abnormalities has continued to rise.  
 
Conclusion 
PMs for cervical cytology have provided a valuable addition to external quality 
assurance procedures in Australia. They have documented continued improvements 
in the aggregate performance, as well as providing benchmarking data and goals for 
acceptable performance for individual laboratories.  
 
Keywords: Cervical cytology; Pap smear; quality assurance; cytopathology; 
gynaecological 
Introduction 
The Australian cervical screening program, based primarily on the conventional Pap 
smear, has been highly successful in reducing the incidence of and mortality from 
cervical cancer1. The quality of cervical cytology reporting by Australian laboratories 
has been an integral factor in this achievement, and has in part been facilitated by 
the development of appropriate standards for laboratories reporting cervical cytology. 
Performance Measures (PMs) for Australian Laboratories Reporting Cervical 
Cytology are a set of key quantifiable criteria that allow comparison of performance 
for individual laboratories. The measures apply to routine cervical smears collected 
from asymptomatic women as part of the screening program. 
 
PMs were first trialled in Australia with two pilot studies in 1994 and 1995. 
Participation was voluntary and involved eleven laboratories in 1994 and fifty in 1995. 
The process was overseen by the Working Party on Quality Assurance in Cervical 
Cytology, under the aegis of the Advisory Committeee to the National Cervical 
Screening program, and administered by the RCPA Cytopathology Quality 
Assurance Program (RCPA QAP). 
 
The trials were useful in developing and refining data collection and analysis and in 
setting appropriate standards for each measure. Rationale for the measures and data 
supporting the suggested acceptable standards were published by the National 
Screening Program in 19962. Participation in the PMs was mandated in 19973 and, 
from 1 July 1999, National Association of Testing Authorities (NATA)/RCPA 
inspections for NATA/RCPA registration and accreditation purposes have included 
an assessment of laboratory performance against the measures. In 2004, oversight 
of the PMs was moved to the National Pathology Accreditation Advisory Council 
(NPAAC) and the measures were revised4. 
 This paper summarises data submitted to the RCPA QAP for PMs in the ten years 
since 1999 when participation became mandatory for Australian laboratories 
reporting cervical cytology. Trends in the aggregate data submitted by all eligible 
laboratories for the various measures and the performance of laboratories against 
the suggested acceptable standards are discussed. 
 
Materials and Methods 
Data for the PMs are self-reported by laboratories with the assistance of information 
provided by State and Territory Pap Test Registers. Data is submitted for the 
previous calendar year. Up until 2005 laboratories reported on five measures relating 
to the profile of reporting, accuracy of reports predicting a high grade epithelial 
abnormality, the accuracy of negative reports and turn-around-times: 
1. Proportion of specimens reported as unsatisfactory. Suggested acceptable 
standard: not < 0.5%, not >5%. 
2. Proportion of technically satisfactory smears collected by general practitioners 
(GPs) and nurses reported in the categories: negative, high grade (HG) 
epithelial abnormality; abnormal. These data were also collected for all 
specimens reported, regardless of the specimen collector, but no suggested 
standard was set as these data include diagnostic smears. Suggested 
acceptable standard: not <0.5% HG epithelial abnormality (up to 2005); not 
<0.7% HG epithelial abnormality or possible HG epithelial abnormality (2006 
onwards). 
3. Proportion of women with a cytological report of high grade intraepithelial 
abnormality where histology, taken within six months, confirms the abnormality 
as a high grade intraepithelial abnormality or malignancy. Suggested 
acceptable standard: not <65% confirmed. 
4. Proportion of women with a histological diagnosis of CIN 3 having cells 
consistent with, or suggestive of, a high grade squamous epithelial 
abnormality identified on review of slides which were originally reported as 
negative within the preceding 24 months. For laboratories operating in some 
states and territories Registry data was not available up until 2004, so the 
slide review was based on women with a cytological diagnosis of CIN 3. 
These data are not included in this summary. Suggested acceptable standard: 
not >20% (until 2005), not >10% (2006 onwards). 
5. Proportion of smears reported within 5 working days. Suggested acceptable 
standard: not <90%. 
 
From 2005 a number of changes were introduced to the measures and the data 
collection process. The changes reflected the maturity of the screening program, the 
development of cervical cytology Registers, changes in reporting terminology, 
participant feedback and the accumulated experience.  
 
Measure 2 relating to the detection rate for high grade abnormalities was changed to 
encompass reports of possible, as well as definite, high grade abnormality, and the 
suggested standard was increased to not less than 0.7% of technically satisfactory 
specimens reported. Previously this was not less than 0.5% reported as definite HG 
abnormality. The proportion of specimens reported as HG abnormality was also age-
standardised using the Australian 2001 Standard Population data. This was done to 
to adjust for any underlying differences in the age profile of specimens reported by 
different laboratories. Additionally, the standard that not greater than 96% of smears 
collected by GPs and nurses be reported as negative was dropped. The standard 
that not more than 14% of technically satisfactory smears be reported as abnormal 
was retained. 
 
Measure 3 relating to the positive predictive value of a cytological diagnosis of HG 
abnormality was expanded to include a similar measure for smears reported as 
possible HG abnormality. 
 
Measure 4 was also expanded to include review of smears reported as negative from 
women with cervical histology of all HG intraepithelial lesions (CIN 2, CIN 3, 
adenocarcinoma in situ (AIS) and mixed in situ lesions) in the previous 30 months. 
 
Measure 5 relating to turn-around-time was dropped. Data collection for this was 
problematic for laboratories and competitive pressure was thought to make this less 
of a problem in Australia than in other countries. The requirement for timely reporting 
of cervical smears was moved to the NPAAC Requirements for Gynaecological 
(cervical) cytology. Data relating to PM 5 will therefore not be included in this review. 
 
Data submission since 2005 occurs twice yearly, with data for the reporting profile 
(Measures 1 and 2) submitted early in the year and measures requiring follow-up 
information (Measure 3 and 4) submitted in October. Reporting profile data is thus 
more timely, being available in March for the previous calendar year. 
 
Data submitted to the RCPA QAP is collated and reported to laboratories in 
individualised reports that list their laboratory data and compare it with aggregate 
data for all participating laboratories. A graphical display (bar graph) also charts the 
data of all laboratories for each measure. This laboratory report, along with 
Certificates of participation, must be made available at the time of NATA/RCPA 
inspection.  
 
Definitions 
The following definitions were used in data collection and analysis: 
 
A specimen was defined as the final report based on the combined result from a 
conventional cervical smear(s) and any liquid based cytology tests and/or automated 
screening. 
 
Negative comprises those specimens in which no abnormal cells were detected plus 
smears in which benign reactive and/or inflammatory cellular change was reported. 
 
High grade intraepithelial abnormality includes HSIL and cervical AIS. 
 
High grade epithelial abnormality includes HSIL, cervical AIS, and carcinoma 
(squamous, glandular or mixed). 
 
Possible HG abnormality includes possible HG squamous and possible HG glandular 
diagnoses. 
 
Results 
Table 1 summarises participation in the PMs. Over the ten years since 1999 the 
number of laboratories reporting cervical cytology has fallen from 84 to 60, although 
the total number of cervical cytology specimens has remained fairly constant at 
around two million per annum. Of these about 1.7 million are reported as being 
collected by GPs or nurses. A small number of laboratories in each year reported 
only specimens collected in specialist clinics and therefore were not subject to the 
reporting profile standards for PM 2. 
 
Figure 1 charts the trend in aggregate data for PM 1, the reporting rate for 
unsatisfactory specimens and the proportion of laboratories falling outside the 
suggested acceptable standard of between 0.5% and 5% of specimens. There was a 
steady but slight rise in the reporting rate from 1.8% in 1998 to 2.3% in 2005, with the 
rate appearing to stabilise at around 2.2% since then.  A decline in the proportion of 
laboratories with data outside the suggested acceptable standard has occurred. In 
1998, 13% of laboratories (11/84) were outside the standard, with seven reporting 
>5% unsatisfactory and four <0.5% unsatisfactory. In 2007 no laboratories failed to 
meet the standard. Two laboratories (4%) fell outside the suggested range in 2008. 
 
Figure 2A shows the aggregate data for reporting rates for HG abnormalities and for 
possible HG abnormalities in specimens collected by nurses and GPs. Both rates 
have shown a rise since 2000 with a peak in 2003.  The HG abnormality rate has 
risen from 0.55% in 2000 to 0.63% in 2008. Over the same time period the possible 
HG rate has risen from 0.39% to 0.52%. Figure 2B plots the proportion of abnormal 
results reported as HG and possible HG over the study period. A trend towards 
reporting a greater proportion of abnormals as HG or possible HG is evident. For 
example, reports of possible HG represented 6.6% of abnormal reports in 2002, but 
9.6% in 2008. 
 
Since 2005, PM 2 has related to the proportion of satisfactory specimens collected by 
GPs and nurses that are reported as HG or as possible HG abnormalities age 
standardised. This proportion has risen slightly, from 1.17% in 2005 to a high of 
1.32% in 2007. In 2008, 20,310 specimens collected by GPs and nurses were 
reported as a HG or possible HG abnormality, with an age standardised rate of 
1.24%. 
 
Figure 2C plots the proportion of laboratories reporting less than the recommended 
rate of 0.5% HG abnormalities, or, after 2005, <0.7% HG or possible HG 
abnormalities. This has fallen from a peak of 42% (29/69) of laboratories in 2001, 
reporting 25% of all specimens collected by GPs and nurses, to 13% (7/55) of 
laboratories reporting 1.5% of all similar specimens in 2008. This improvement was 
apparent before the alteration of the standard in 2005 to include possible HG 
abnormality reports, with the greatest improvement occurring between 2001 and 
2003. 
 
The proportion of technically satisfactory specimens reported as abnormal over the 
ten years from 1998 is charted in Figure 2D. This has shown a slight fall from 6.1% in 
1998 to 5.5% of specimens in 2008, when 96,861 specimens were reported as non-
negative. The number of laboratories reporting >14% specimens collected by GPs 
and nurses as abnormal has fallen from six (8.8%; 6/68) in 1998 to just one (1.8%; 
1/55) laboratory in 2007 and 2008 (Figure 2D). 
 
Figure 3A displays PM 3 (a & b) aggregated data for all laboratories for the period 
1998-2008. PM 3a reports the positive predictive value (PPV) of a cytological report 
of HG intraepithelial abnormality, reporting the percentage of cases where histology, 
taken within six months, confirms the abnormality as a HG intraepithelial abnormality 
or cancer. This measure has also shown a trend of improvement over the ten year 
study period. Whereas 72% of the 11,334 cytological reports of HG intraepithelial 
abnormality issued in 1998 where confirmed on histology, 78% of 14,789 were 
confirmed in 2008. Follow-up histology results for non-correlating cases in 2008 
consisted of  low grade abnormalities (13.5% of all cases with histology), negative 
(8.4%) and unsatisfactory (0.3%). The improvement in PPV over the study period 
was reflected in the proportion of laboratories failing to meet the standard of not 
<65% of reports confirmed on histology (Figure 3B). Sixteen percent (13/80) of 
laboratories in 1998 were below this standard, while only 3.8% (2/61) were in 2008. 
 
Since 2005, a PPV measure was also introduced for reports of possible HG 
abnormality, PM 3(b). Figure 6 indicates that the PPV for reports of possible HG 
intraepithelial abnormality has risen by 10% since 2005 to 53% in 2008. In this time 
the proportion of laboratories with <33% of these cases confirmed by histology as a 
HG abnormality has fallen (Figure 3B) from 16% (11/68) in 2004 to 5% (3/61). 
 
Performance Measure 4 reports data on the accuracy of a negative smear result from 
women with histological HG abnormality. Although slightly higher in 1998, the rate 
has been fairly consistent since then at around 3-3.5% of women with a histological 
diagnosis of CIN 3 having cells consistent with, or suggestive of, a high grade 
epithelial abnormality identified on review of slides which were originally reported as 
negative (Figure 4). The widening of cases requiring review from histological reports 
of CIN 3 to all HG abnormalities (squamous, glandular and mixed) and the period of 
retrospective review (24 to 30 months) for cytology specimens since 2005 has been 
accompanied by only a slight rise in the proportion of false negative cases detected 
(3% to 3.3%).  
 
In 2008, 24,230 women had a histological diagnosis of a HG abnormality and cervical 
cytology reported in the previous 30 months. Twenty-three percent (5,470) of them 
had a negative cytology result. Review diagnoses reported for the 5470 women were: 
69.7% negative; 12.9% low grade abnormalities (squamous or glandular); 10.4% 
possible HG abnormalities (squamous or glandular); 4.4% HG abnormality; 1.2% 
unsatisfactory and 1.4% slides unavailable for review. The proportion of women with 
negative smears that on review were identified as true false negatives has been fairly 
constant at around fifteen per cent. 
 
The proportion of laboratories not meeting the standard has fallen since 1998, 
despite the 2004 changes to both the measure, widening the review, and the 
standard, which was tightened from not greater than 20% of women with false 
negative results to not greater than 10%. A maximum of one laboratory per year has 
not met the standard since it was revised in 2004. 
Table 1. Number of laboratories and total specimens reported 1998-2008. 
 
Year of 
reporting 
No. labs 
reporting 
data 
for all 
smears 
Total no. of 
specimens 
reported 
No. of labs 
reporting 
specimens from 
GPs & nurses 
Total no. of 
specimens 
from GPs & 
nurses 
     
1998 84 2,260,892 68 1,718,393 
1999 82 2,107996 70 1,651,998 
2000 83 1,992,282 72 1,587,958 
2001 76 2,100,951 69 1,685,894 
2002 76 2,155,088 73 1,765,372 
2003 70 2,050,583 65 1,642,285 
2004 70 2,093,488 63 1,740,696 
2005 66 2,117,342 61 1,769,361 
2006 60 2,085,871 55 1,752,066 
2007 63 2,135,214 57 1,801,547 
2008 60 2,099,209 55 1,764,804 
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Figure 1. Performance Measure 1 data - aggregate data for all laboratories1998-
2008. Proportion of specimens reported as technically unsatisfactory (% unsat 
reports) and proportion of laboratories reporting < 0.5% or >5% of specimens as 
technically unsatisfactory (% labs outside std). 
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Figure 2. Performance Measure 2A. Aggregate data for the proportion of technically 
satisfactory specimens collected by GPs and nurses reported as a HG abnormality 
(CIN 2, CIN 3, AIS, mixed cervical lesions & invasive cervical carcinoma) and as 
possible HG abnormality (squamous and glandular). Data for possible HG was not 
collected prior to 2000. 
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Figure 2B. Performance Measure 2 aggregate data 1998-2008 for specimens 
collected by GPs and nurses. The percentage of abnormal reports reported as HG 
abnormality or possible HG abnormality. 
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Figure 2C.  Performance Measure 2. Proportion of laboratories reporting <0.5% of 
technically satisfactory specimens collected by GPs and nurses as a HG epithelial 
abnormality, or since 2005, <0.7% as a HG epithelial abnormality or possible HG 
epithelial abnormality.  
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Figure 2D. Performance Measure 2. Aggregate data for the proportion of technically 
satisfactory specimens collected by GPs and nurses reported as abnormal 1998-
2008 and the proportion of laboratories reporting >14% of specimens collected by 
GPs or nurses as abnormal.  
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Figure 3A. Performance Measure 3 aggregated data 1998-2008. Proportion of 
women with a cytological report of HG intraepithelial abnormality where histology, 
taken within six months, confirms the abnormality as a HG intraepithelial 
abnormality (PM 3a) and proportion of women with a cytological report of possible 
HG abnormality where histology, taken within six months, confirms the 
abnormality as a HG abnormality (PM 3b). 
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Figure 3B. Performance measure 3 data 1998-2008. Proportion of laboratories 
with <65% of women with a cytological report of HG intraepithelial abnormality 
where histology, taken within six months, confirms the abnormality as a HG 
intraepithelial abnormality (PM 3a) and proportion of laboratories with <33% of 
women with a cytological report of possible HG abnormality where histology, 
taken within six months, confirms the abnormality as a high grade abnormality 
(PM 3b). 
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Figure 4.  Performance Measure 4 aggregate data 1998-2008. Proportion of women 
with a histological diagnosis of CIN 3 having cells consistent with, or suggestive of, a 
high grade squamous epithelial abnormality identified on review of slides which were 
originally reported as negative within the preceding 24 months (% women with false 
negatives (FNs) and the proportion of laboratories outside the standard (not >10%) 
for PM 4. After 2005 the measure included review of smears reported as negative 
from women with cervical histology of all HG intraepithelial (squamous and glandular) 
lesions in the previous 30 months.  
 Discussion 
The data presented documents the generally high and improving quality of cervical 
cytology reporting in Australia. Laboratories have shown improvement against all 
measures over the ten years reviewed, both in the aggregate performance and 
compliance with suggested acceptable standards. 
 
The rate of reporting specimens as unsatisfactory (PM 1) shows greater uniformity 
over time and less outliers. The introduction of a formal definition for adequacy with 
the Australian modified Bethesda terminology in 2004 does not appear to have 
markedly influenced this rate. Liquid based cytology has been shown to produce a 
significant reduction in inadequacy rates5. However, the uptake of this technology in 
Australia, where a government rebate is not available, has not sufficiently altered in 
the study period to impact upon the national rate. A rate of around 2% unsatisfactory 
reports is also significantly lower than rates in England when this was a major 
impetus for conversion to liquid based technologies.  
 
Australian state and territory registry data show a rise in the rate of HG abnormalities 
detected by histology per 1000 women screened (age standardised) from 6.2 in 1998 
to 7.0 in 2007, with a peak of 7.5 between 2002 and 20051. The acceptable standard 
for cytology was set at not less than 0.7% of specimens reported as HG or possible 
HG abnormality when the PMs were reviewed in 2004. In 2008, seven (13%) 
laboratories, reporting just 1.5% of all smears, failed to meet this standard.  
 
Comparison of Australian data with international experience is difficult due to 
differences in reporting terminology and organisational aspects of screening 
programs, such as screening intervals.  For example in England, where screening is 
recommended three yearly for women aged 25 to 64 years,  the reported rate for 
moderate dyskaryosis or more severe (equivalent to the Australian HG abnormality) 
was 1.2% in 2008-96. Acceptable standards in England are set as a target range, 
based on the 10th – 90th percentiles of data submitted from laboratories. In 2008-9 
the target range in England was 0.8-1.5%. In Australia a specific lower limit (not less 
than 0.7%) for the standard was set as a goal for laboratories, based on histological 
data. 
 
Performance measure data relating to the profile of reporting for ‘community’ smears 
and the PPV of cytology reporting demonstrates continued improved cytological 
detection of high grade abnormalities over the study period. Laboratories are 
reporting a greater proportion of specimens as definite or possible HG abnormality 
and a greater proportion of these reports are being confirmed by subsequent 
histology. The true underlying incidence of HG abnormality is not known, hence it is 
not possible to definitely determine if the increase in HG abnormality reports reflects 
improved detection or an actual rise in disease incidence. Nevertheless, the rise in 
the proportion of HG abnormality reports is partly due to a higher proportion of 
abnormal cases being classified as definite or possible HG abnormality. Since 2006, 
there has been a 10% rise in the proportion of abnormal reports classified as 
possible HG abnormality, which may in part reflect the introduction of new reporting 
terminology (AMBS 20047) and management recommendations. Despite this, the 
PPV for possible HG abnormalities has also continued to rise. 
 
In 2008, 78% of cytological predictions of HG abnormality were confirmed by cervical 
biopsy within six months. This may underestimate the true PPV of cervical cytology 
as the measure correlates cytology results with any cervical biopsy, rather than only 
LLETZ or cone biopsy specimens. Nevertheless, it appears comparable with 
international performance. A CAP Q-Probes study8 from 1996 reported biopsy 
confirmation of HSIL in 75% of 3258 cases reported by 346 laboratories. English data 
for 2008-9 indicate most laboratories reported a PPV for CIN 2 or more severe in the 
range of 75-90%6. 
 
Aggregate data for PM 4, the review of negative specimens from women with 
histological HG abnormalities, has shown little change since 2000, with around 3% of 
women shown to have false negative cytology in each year. This may reflect the 
underlying ‘irreducible error rate’ of conventional cervical cytology that is 
compensated for by regular screening9,10. A Q-Probes study11 involving 312 
laboratories reviewing 3,681 cases reported as negative or benign cellular change 
reported a review diagnosis of ASCUS 9%, LSIL 4.7%, HSIL 4.6%, SCC 0.1% and 
AGUS/Glandular intraepithelial lesion 0.8%. Differences in terminology make 
comparison of these data difficult. For example there was no category for ‘possible 
HG abnormality’ in the Q-Probes study and these cases would have been included in 
the ASCUS or LSIL categories. However the rate of false negative definite HG 
abnormality is quite similar to the 4.7% reported in PM 4 for 2008. 
 
PMs have been a very useful addition to the program of external quality assurance 
for Australian cervical cytology laboratories, providing valuable information for 
external inspectors. The measures do, however, have a number of limitations. The 
retrospective nature of data collection means that laboratories must be operating for 
some time before meaningful data is available, particularly for the review and 
correlation measures (PMs 3 and 4). Additionally, because no annual minimum 
volume has been set for Australian laboratories, laboratories reporting small numbers 
of Pap smears are more likely to not meet standards due to chance alone. For this 
reason the PMs document includes detailed information on the investigation of 
outlying data that emphasises the importance of viewing both the trends in data and 
the interaction of different measures. It should also be emphasised that PMs, while 
providing useful statistical data, are only one of many quality indicators for 
laboratories and should be examined in conjunction with other facets of laboratory 
practice. 
 
In addition to quality monitoring, the PMs data also provide a useful summary of the 
findings that can be expected in ‘community’ smears. Around one in fifty screening 
specimens collected in Australia will be reported as technically unsatisfactory and 
one per 100 reports will be HG or possible HG abnormality. Around 75% of HG and 
50% of possible HG abnormalities will be confirmed as HG abnormality on histology. 
Around 25% of women with histological HG abnormality will have a negative smear 
result in the previous 30 months and about 3% of them will have received a falsely 
negative cytology result due to laboratory error. 
 
PMs for cervical cytology have been useful in documenting Australian laboratory 
performance and have assisted continued quality improvement by providing 
benchmarking data and goals for acceptable performance. The proportion of all 
smears reported in Australia by laboratories not complying with the suggested 
acceptable standards is now very low. The future challenge will be in setting 
appropriate standards relevant to an HPV immunised population. 
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